Back |
home / stock / ipsc / ipsc message board
Subject | By | Source | When |
---|---|---|---|
952: Enabling the Engineering of iPSC Based Cell | jondoeuk | investorshub | 05/02/2022 9:45:36 PM |
ASGCT title: | jondoeuk | investorshub | 04/29/2022 11:22:52 PM |
Preclinical data on mbIL-15 https://ashpublications.org/blood/article/124/7/1081 | jondoeuk | investorshub | 02/21/2022 3:31:58 AM |
Data Disclosures | jondoeuk | investorshub | 02/14/2022 1:02:30 AM |
Posters https://www.centurytx.com/wp-content/uploads/2022/01/Induced-pluripotent | jondoeuk | investorshub | 02/14/2022 1:01:51 AM |
PR https://www.globenewswire.com/news-release/2021/12/16/2353430/0/en/Century-Th | jondoeuk | investorshub | 12/16/2021 9:10:21 PM |
R&D Update (Dec 16, from 8:00 AM to | jondoeuk | investorshub | 12/07/2021 1:04:28 AM |
ASH abstracts | jondoeuk | investorshub | 11/04/2021 6:09:40 PM |
They are also working on an iT (BCMA | jondoeuk | investorshub | 07/01/2021 4:29:18 PM |
News, Short Squeeze, Breakout and More Instantly...
Century Therapeutics Inc. Company Name:
IPSC Stock Symbol:
NASDAQ Market:
Century Therapeutics Inc. Website:
In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting Encouraging preliminary efficacy in heavily pretreated R/R NHL at initial dose levels Novel cell-free DNA m...
In vitro data showcases CNTY-101’s ability to induce CD19-specific cytolysis of B-cells and potential to treat B-cell driven autoimmune diseases including systemic lupus erythematosus (SLE) Preclinical data demonstrates potential utility of using a synthetic ligand targeting CD30...
- Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE) - Closed $60 million private placement led by Bain Capital Life Sciences supporting accelerated expansion in autoim...